25.53
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$24.59
Aprire:
$24.07
Volume 24 ore:
2.07M
Relative Volume:
1.04
Capitalizzazione di mercato:
$140.82M
Reddito:
$90.12M
Utile/perdita netta:
$-276.06M
Rapporto P/E:
-17.49
EPS:
-1.46
Flusso di cassa netto:
$-193.47M
1 W Prestazione:
-12.33%
1M Prestazione:
+3,106%
6M Prestazione:
+2,557%
1 anno Prestazione:
+2,082%
Nektar Therapeutics Stock (NKTR) Company Profile
Nome
Nektar Therapeutics
Settore
Industria
Telefono
(415) 482-5300
Indirizzo
455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA
Confronta NKTR con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
NKTR
Nektar Therapeutics
|
25.53 | 140.82M | 90.12M | -276.06M | -193.47M | -1.46 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Nektar Therapeutics Stock (NKTR) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-04-11 | Aggiornamento | Jefferies | Hold → Buy |
2025-03-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
2025-01-08 | Iniziato | B. Riley Securities | Buy |
2024-12-10 | Iniziato | H.C. Wainwright | Buy |
2024-11-04 | Iniziato | Piper Sandler | Overweight |
2024-09-30 | Ripresa | BTIG Research | Buy |
2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
2023-11-20 | Ripresa | JP Morgan | Underweight |
2023-11-09 | Aggiornamento | TD Cowen | Market Perform → Outperform |
2023-05-10 | Aggiornamento | Jefferies | Underperform → Hold |
2023-02-24 | Downgrade | Jefferies | Hold → Underperform |
2022-08-08 | Downgrade | JP Morgan | Neutral → Underweight |
2022-05-31 | Ripresa | Jefferies | Hold |
2022-04-18 | Downgrade | Goldman | Neutral → Sell |
2022-03-15 | Downgrade | Cowen | Outperform → Market Perform |
2022-03-15 | Downgrade | Mizuho | Buy → Neutral |
2022-03-14 | Downgrade | BTIG Research | Buy → Neutral |
2022-03-14 | Downgrade | BofA Securities | Neutral → Underperform |
2022-03-14 | Downgrade | Stifel | Buy → Hold |
2022-03-14 | Downgrade | William Blair | Outperform → Mkt Perform |
2022-03-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
2021-11-08 | Aggiornamento | The Benchmark Company | Hold → Buy |
2021-09-10 | Iniziato | BofA Securities | Neutral |
2021-06-28 | Aggiornamento | Stifel | Hold → Buy |
2021-05-18 | Ripresa | Goldman | Neutral |
2021-02-22 | Downgrade | The Benchmark Company | Buy → Hold |
2021-01-06 | Iniziato | Stifel | Hold |
2020-09-14 | Iniziato | JP Morgan | Neutral |
2020-06-10 | Downgrade | CFRA | Hold → Sell |
2020-05-12 | Reiterato | H.C. Wainwright | Neutral |
2020-04-22 | Iniziato | The Benchmark Company | Buy |
2020-03-30 | Aggiornamento | Goldman | Sell → Neutral |
2020-03-04 | Iniziato | Barclays | Overweight |
2020-02-03 | Aggiornamento | Mizuho | Neutral → Buy |
2019-10-24 | Iniziato | Oppenheimer | Perform |
2019-10-08 | Downgrade | Goldman | Buy → Sell |
2019-08-09 | Downgrade | JP Morgan | Overweight → Neutral |
2019-08-09 | Downgrade | Jefferies | Buy → Hold |
2019-08-09 | Downgrade | Mizuho | Buy → Neutral |
2019-03-15 | Iniziato | SVB Leerink | Mkt Perform |
2018-12-13 | Iniziato | Goldman | Buy |
2018-06-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
2018-06-04 | Reiterato | H.C. Wainwright | Buy |
2018-04-20 | Iniziato | Seaport Global Securities | Buy |
2018-04-13 | Ripresa | Piper Jaffray | Overweight |
2018-04-06 | Reiterato | Mizuho | Buy |
2018-04-02 | Ripresa | H.C. Wainwright | Buy |
Mostra tutto
Nektar Therapeutics Borsa (NKTR) Ultime notizie
Alopecia Areata Market Expected to Experience Major Growth by 2034, According to DelveInsight | Pfizer, Suzhou Zelgen Biopharma, Eli Lilly/ Incyte, Throne Biotech, Legacy Healthcare - Barchart.com
Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC (NKTR) - Seeking Alpha
Nektar Therapeutics (NASDAQ:NKTR) Shares Fly 29% But Investors Aren't Buying For Growth - simplywall.st
Nektar therapeutics outlines REZOLVE-AD phase 2b data and financial position for Q2 2025 - MSN
Nektar (NKTR) Trading Paused Ahead of Important Announcement | N - GuruFocus
Nektar Therapeutics Increases Authorized Shares To 390 Million - MarketScreener
Nektar Therapeutics Approves Reverse Stock Split - TipRanks
Millennium Management LLC Sells 536,773 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Natural Killer (NK)-Cell Lymphoma Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
D. E. Shaw & Co. Inc. Grows Stake in Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Metastatic renal cell carcinoma Pipeline 2025: Groundbreaking - openPR.com
BNP Paribas Financial Markets Acquires 73,847 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Nektar Therapeutics Elects New Board, Approves Key Proposals - TipRanks
Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com
Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail
Have Insiders Sold Nektar Therapeutics Shares Recently? - simplywall.st
Nektar Therapeutics (NASDAQ:NKTR) Receives $4.50 Average Target Price from Analysts - Defense World
Moderate to Severe Atopic Dermatitis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsight - GlobeNewswire
Nektar Therapeutics To Present At H.C. Wainwright BioConnect Conference; Webcast At 1:30 PM ET - Nasdaq
Nektar Therapeutics (NASDAQ:NKTR) Rating Lowered to “Sell” at StockNews.com - Defense World
What is William Blair’s Estimate for NKTR Q2 Earnings? - Defense World
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are More Bearish Than They Used To Be - simplywall.st
Voya Investment Management LLC Acquires 121,187 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Q2 EPS Estimate for Nektar Therapeutics Decreased by Analyst - Defense World
GSK’s liver asset play grows group of $1B upfront deals - biocentury.com
Nektar Therapeutics (NASDAQ:NKTR) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference - Kilgore News Herald
Nektar Therapeutics to Participate in the H.C. Wainwright 3rd An - GuruFocus
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down - MSN
Time To Worry? Analysts Are Downgrading Their Nektar Therapeutics (NASDAQ:NKTR) Outlook - Yahoo Finance
Nektar Therapeutics’ (NKTR) Market Perform Rating Reaffirmed at William Blair - Defense World
Anticipated Clinical Trial Results and Financial Stability Justify Buy Rating for Nektar Therapeutics - TipRanks
H.C. Wainwright maintains NKTR stock Buy rating, $6.50 target By Investing.com - Investing.com Nigeria
H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider
Nektar Therapeutics (NASDAQ:NKTR) Stock Position Raised by Wells Fargo & Company MN - Defense World
Barclays PLC Sells 32,476 Shares of Nektar Therapeutics (NASDAQ:NKTR) - Defense World
Dendrimers And Polymer Drugs Conjugate Market to Witness - openPR.com
H.C. Wainwright maintains NKTR stock Buy rating, $6.50 target - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Nektar Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Nektar Therapeutics (NASDAQ:NKTR) Q1 2025 Earnings Call Transcript - Insider Monkey
Nektar Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
BTIG maintains Buy on Nektar stock, price target at $4.00 By Investing.com - Investing.com India
Insiders Sold Nektar Therapeutics At US$1.06, Meanwhile Stock Sits Near US$0.62 - simplywall.st
NEKTAR THERAPEUTICS SEC 10-Q Report - TradingView
BTIG Reiterates Buy Rating on Nektar Therapeutics (NKTR) - StreetInsider
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... By GuruFocus - Investing.com Canada
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and ... - Yahoo Finance
Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Highlights: Advancements in Immunology and Financial Outlook - GuruFocus
Nektar Therapeutics Reports Q1 2025 Financial Results - TipRanks
Q1 EPS Estimates for Nektar Therapeutics Lowered by B. Riley - Defense World
Nektar Therapeutics Azioni (NKTR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Nektar Therapeutics Azioni (NKTR) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Wilson Mark Andrew | Chief Legal Officer |
May 19 '25 |
Sale |
0.67 |
9,996 |
6,697 |
314,296 |
ROBIN HOWARD W | President & CEO |
May 19 '25 |
Sale |
0.67 |
23,208 |
15,549 |
1,063,693 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):